Taxodium distichum pollen allergen (Tax d 1) (Tax d 1)

The immune response to Taxodium distichum (Bald Cypress) pollen allergens is a Type I hypersensitivity reaction mediated by allergen-specific IgE antibodies. The primary allergen, Tax d 1, is a pectate lyase protein that exhibits high sequence homology and cross-reactivity with other Cupressaceae allergens like Cry j 1 from Japanese cedar (PMID: 10471518). Upon inhalation, these allergens cross-link IgE bound to FcεRI receptors on mast cells and basophils in the respiratory mucosa, leading to the degranulation and release of inflammatory mediators such as histamine and leukotrienes (PMID: 15585361). This cascade results in the clinical manifestations of seasonal allergic rhinitis, conjunctivitis, and exacerbation of asthma. While the allergens themselves are not therapeutic targets in the traditional sense, they are the focus of diagnostic testing and allergen-specific immunotherapy, which seeks to modify the immune system's long-term response to these proteins (allergen.org). Management of the immune response typically involves symptomatic relief through pharmacological agents that block the effects of released mediators or suppress the underlying inflammatory process.

Other names

Bald cypress pollen allergenTax d 1Tax d 2Tax d 3Tax d 4Pectate lyase Tax d 1

Pharmacological intervention targets the downstream effects of the immune response, such as H1 receptor antagonism (antihistamines), leukotriene receptor blockade (montelukast), or IgE neutralization (omalizumab). Allergen-specific immunotherapy (AIT) aims to induce peripheral T-cell tolerance and increase regulatory T-cell activity (PMID: 28923131).